What does Trump 2.0 mean for pharma?

Explore how Trump’s healthcare picks, anti-pharma allies, and tariff pressures could reshape FDA policy, global market access, drug pricing, vaccines, and emerging drug markets.

Building the next generation of biotech companies  

The panel examined how emerging biotech leaders are advancing breakthrough technologies while overcoming funding and regulatory hurdles to build the next wave of innovative companies.

Pharma in China - delivering or decoupling?

Unpack the strategic implications of China’s biopharma expansion, hear how global companies are adjusting licensing frameworks, IP protections, and international partnerships in response to rising external pressures..

AI in pharma – From trial and error to business as usual

The panel discussed how pharma can embed AI into everyday R&D and operations by overcoming bottlenecks, improving collaboration, and defining the role of human expertise.